Consensus Dermata Therapeutics, Inc.

Equities

DRMA

US2498454055

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
4.2 ^USD	-19.23%		-21.94%	-54.10%

Mar. 21	Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 05	Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	MT

Evolution of the average Target Price on Dermata Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

eb9a373fb3c3e901872fe70d39bb1._Az6eUARYdrxrdPhLjvqLBHht4d1NS9uzuaOYtdEAZc.q2m5FQ1wLoiH2KO1fm3dVXmY2N07Q20sl7nmFoYgV_6YfqIQbTwb7KTb4w~ccc3c8950e596947b3575d0005f70738

Analyst Recommendations on Dermata Therapeutics, Inc.

Maxim Adjusts Price Target on Dermata Therapeutics to $4 From $16, Keeps Buy Rating	23-03-23	MT
DERMATA THERAPEUTICS : Brookline Capital Starts Dermata Therapeutics at Buy with $14 Price Target	21-09-21	MT
DERMATA THERAPEUTICS : Maxim Starts Dermata Therapeutics at Buy with $9 Price Target	21-09-14	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.2 USD

Average target price

22.5 USD

Spread / Average Target

+435.71%

High Price Target

22.5 USD

Spread / Highest target

+435.71%

Low Price Target

22.5 USD

Spread / Lowest Target

+435.71%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Dermata Therapeutics, Inc.

Maxim
Brookline Capital Management

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar